IPO Files Amicus Brief in Support of Respondents in Bowman v. Monsanto

by McDonnell Boehnen Hulbert & Berghoff LLP
Contact

IPO #2In an amicus brief filed in support of respondents Monsanto Co. et al. late last week, the Intellectual Property Owners Association (IPO) urges the Supreme Court to find that the petitioner's replanting of commodity seed was an infringing act that constituted a reconstruction of Monsanto’s patented recombinant seed.  The IPO contends that "[a]ny other decision would unnecessarily impede progress in the agricultural biotechnology field, with deleterious consequences for developing technologies to address the need for increasing food production and reducing hunger, in the U.S. and globally."

The case arose as the result of a farmer (Mr. Bowman) replanting Monsanto's patented Roundup Ready® seed.  Mr. Bowman had purchased the seed from one of Monsanto's licensed seed producers, with the sale being subject to a Technology Agreement that permitted Mr. Bowman to, inter alia, "use the seed containing Monsanto gene technologies for planting a commercial crop only in a single season" and "not save any crop produced from this seed for replanting, or supply saved seed to anyone for replanting."  While Mr. Bowman complied with these provisions with respect to a first planting, Mr. Bowman used cheaper "commodity seed" (i.e., seed obtained from local grain elevators) in a second planting.  After planting the commodity seed, Mr. Bowman tested the second crop for Roundup® resistance, and found that substantial amounts of the seed were resistant.  He then used Roundup® on these plantings and replanted this seed.  The District Court granted summary judgment of patent infringement and entered judgment against Mr. Bowman, and the Federal Circuit affirmed.

MonsantoWriting in support of Monsanto, the IPO asserts that "the Federal Circuit correctly found that the doctrine of patent exhaustion does not absolve Mr. Bowman from infringement."  The brief notes that "[w]hile patent exhaustion would have prevented Monsanto from restricting the distribution or use of [the] original seeds [that were the subject of an authorized sale by Monsanto], those original seeds were completely consumed (as intended) in the growing of the first crop."  Mr. Bowman instead used commodity seeds, which were not the subject of an authorized sale by the patentee, and which the IPO brief contends "constitute an entirely new manufacture and, as such, are not subject to the doctrine of patent exhaustion under this Court’s jurisprudence."

Arguing that "Monsanto's rights to its patented seed are infringed by Mr. Bowman's replanting, which is not merely a use but a complete remaking of new seeds," the brief contends that Mr. Bowman’s actions can be distinguished from the noninfringing use of Intel chipsets in Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), after the patent rights in those chipsets were exhausted by sale.  In particular, the brief states that in the instant case, "there was no authorized, unrestricted sale by Monsanto of the seed used by Mr. Bowman that would exhaust patentee's patent rights," adding that "[t]he original, authorized seed sold by Monsanto was consumed in the first planting," and further, that "[t]he commodity seed purchased by Mr. Bowman was neither made by nor sold by Monsanto."

The IPO brief also argues that the lack of patent exhaustion in the instant case is consistent with the Supreme Court's precedent concerning repair and replacement.  In particular, the brief states that "Mr. Bowman’s replanting of commodity seed was no mere 'repair' of the patented article," noting that "the original seed sold by Monsanto had performed its use and had been consumed in the very first planting."  The brief contends that "Mr. Bowman reconstructed the crop by replanting the commodity seed (thereby creating a third generation of seed capable of reconstructing a third crop), and it was this act that constituted an infringing reconstruction of Monsanto's patented seed."

The IPO further argues that the Supreme Court would not be creating a special exemption for patented seed by upholding Monsanto’s patent rights, as argued by Mr. Bowman.  The brief notes, for example, that "infringement liability based on copying patented technology is not unique to seeds, but is a property shared with other technologies, including computer software and the emerging field of nanotechnology."  The brief also states that:

Mr. Bowman’s characterization of Monsanto's patented seed as "self-replicating" is a red herring that disregards Mr. Bowman's own affirmative infringing actions.  Mr. Bowman purchased the commodity seeds, replanted the seeds, grew the seeds in the presence of Roundup® to eliminate undesirable weeds from his crop and reaped the economic rewards of his infringing actions.  Mr. Bowman cannot avoid the consequences of his agency in performing these infringing actions merely by characterizing Monsanto's patented seeds as "self-replicating;" the commodity seeds did not plant themselves.

Declaring that "[t]he fruits of the second 'green revolution' provided by recombinant seeds such as Monsanto’s seeds here are important not only for the U.S. economy but to address the needs of a burgeoning global population," the brief argues that "[n]one of the benefits of [genetically modified plants] would survive as viable economic alternatives [to unmodified plants] if the purchaser of a first seed could reconstruct the patented invention by replanting patented seed indefinitely, which would occur if 'making' is considered an exhausted 'use.'"  The brief states that "[n]o technology could survive if infringers were permitted to plunder the fruits of patented invention in this manner."

Pointing to erythropoietin-producing recombinant cells in Amgen, Inc. v. Elanex Pharms., Inc., No. C93-1483D, 1996 U.S. Dist. LEXIS 22015, at *9 (W.D. Wash. Feb. 6, 1996), the brief notes that "[p]atented seeds are not the only technologies where 'making' has properly been considered as a separate infringing activity."  The brief then argues that:

If the doctrine of patent exhaustion were improperly extended to the routine growth of recombinant host cells, this could have a devastating effect on investment in the production of new biologic drugs made from recombinant cells.  If patents on recombinant cells used to make new drugs could be easily circumvented by reliance on the exhaustion doctrine, the deleterious effects on the pharmaceutical industry could be even greater than in the agricultural arena.

Patent Docs plans to review a number of the briefs filed in this case, including the briefs on the merits filed by the petitioner and the respondents, as well as several of the amicus briefs that were filed.  According to the docket for this case on the Supreme Court website, amicus briefs have been filed by Knowledge Ecology International, the Automotive Aftermarket Industry Association et al., the American Antitrust Institute et al., the Public Patent Foundation, the Center for Food Safety and Save Our Seeds, the United States government, BayhDole25, Inc., CropLife America, BSA - The Software Alliance, the American Seed Trade Association, the Washington Legal Foundation, the Biotechnology Industry Organization, CropLife International, the American Intellectual Property Law Association, Ecomonists, and law professor Christopher M. Holman.  Argument for the case is scheduled for February 19, 2013.

Note: the IPO brief was co-authored by Patent Docs author Dr. Kevin Noonan.

 

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP
Contact
more
less

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Privacy Policy (Updated: October 8, 2015):
hide

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.

Security

JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at info@jdsupra.com. In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at: info@jdsupra.com.

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.